Sylvain Baruchel

7.8k total citations · 1 hit paper
134 papers, 5.7k citations indexed

About

Sylvain Baruchel is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Sylvain Baruchel has authored 134 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Neurology, 51 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Sylvain Baruchel's work include Neuroblastoma Research and Treatments (49 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Glioma Diagnosis and Treatment (19 papers). Sylvain Baruchel is often cited by papers focused on Neuroblastoma Research and Treatments (49 papers), Cancer, Hypoxia, and Metabolism (20 papers) and Glioma Diagnosis and Treatment (19 papers). Sylvain Baruchel collaborates with scholars based in Canada, United States and Italy. Sylvain Baruchel's co-authors include Robert S. Kerbel, Shan Man, Giannoula Klement, Janusz Rak, Daniel J. Hicklin, Peter Böhlen, Katherine Clark, Herman Yeger, Diana Stempak and Iris Epstein and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Genetics.

In The Last Decade

Sylvain Baruchel

133 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 956 citations Giannoula Klement, Sylvain Baruchel et al. profile →

Peers

Sylvain Baruchel

ONCOL

NEURO

PRM

Stacey L. Berg United States

Glenn M. Marshall Australia

David J. Liewehr United States

David M. Ashley United States

Mary Porteous United Kingdom

Anthony Robbins United States

Joellen M. Schildkraut United States

Eugene S. Kim United States

Jeremy Brown United Kingdom

Claudio Ceccarelli Italy

Stacey L. Berg United States

Sylvain Baruchel

1.6k ×0.7

1.7k ×1.1

ONCOL

835 ×0.7

NEURO

427 ×0.4

857 ×0.8

PRM

Citations per year, relative to Sylvain Baruchel Sylvain Baruchel (= 1×) peers Stacey L. Berg

Countries citing papers authored by Sylvain Baruchel

Since Specialization

Citations

This map shows the geographic impact of Sylvain Baruchel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Baruchel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Baruchel more than expected).

Fields of papers citing papers by Sylvain Baruchel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Baruchel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Baruchel. The network helps show where Sylvain Baruchel may publish in the future.

Co-authorship network of co-authors of Sylvain Baruchel

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Baruchel. A scholar is included among the top collaborators of Sylvain Baruchel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Baruchel. Sylvain Baruchel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Sushil, Jessica D. Sun, Libo Zhang, et al.. (2018). Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models. Translational Oncology. 11(4). 911–919. 14 indexed citations

Zhang, Libo, Paula Marrano, Bing Wu, et al.. (2015). Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. Clinical Cancer Research. 22(11). 2697–2708. 25 indexed citations

Zhang, Libo, Paula Marrano, Sushil Kumar, et al.. (2013). Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors. Clinical Cancer Research. 19(21). 5972–5983. 48 indexed citations

Bender, Julia Glade, Alice Lee, Joel M. Reid, et al.. (2013). Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology. 31(24). 3034–3043. 125 indexed citations

Kelley, Robin Kate, Justin H. Hwang, Mark Jesus M. Magbanua, et al.. (2013). A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British Journal of Cancer. 109(7). 1725–1734. 33 indexed citations

Widemann, Brigitte C., AeRang Kim, Elizabeth Fox, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(21). 6011–6022. 90 indexed citations

Bender, Julia Glade, Susan M. Blaney, Scott C. Borinstein, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(18). 5081–5089. 16 indexed citations

Bouffet, Éric, Regina I. Jakacki, Stewart Goldman, et al.. (2012). Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. Journal of Clinical Oncology. 30(12). 1358–1363. 143 indexed citations

Kumar, Sushil, Reza Bayat Mokhtari, Herman Yeger, & Sylvain Baruchel. (2012). Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement. Expert Opinion on Drug Discovery. 7(11). 1093–1106. 5 indexed citations

10.

Gesundheit, Benjamin, Patricia C. Parkin, Mark Greenberg, et al.. (2010). The Role of Angiogenesis in the Transformation of Plexiform Neurofibroma into Malignant Peripheral Nerve Sheath Tumors in Children With Neurofibromatosis Type 1. Journal of Pediatric Hematology/Oncology. 32(7). 548–553. 16 indexed citations

11.

Das, Bikul, Herman Yeger, & Sylvain Baruchel. (2006). Squalene protects mice bone marrow hematopoietic and mesenchymal stem cells against high-dose cisplatin in vivo by restoring antioxidant balance: implications in cancer chemotherapy. Cancer Research. 66. 266–266. 1 indexed citations

12.

Das, Bikul, Herman Yeger, Rika Tsuchida, et al.. (2005). A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1α through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma. Cancer Research. 65(16). 7267–7275. 100 indexed citations

13.

Lau, Loretta M. S. & Sylvain Baruchel. (2005). Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children.. PubMed. 12(3). e222–8. 2 indexed citations

14.

Gee, M., Rika Tsuchida, Claudia Eichler-Jonsson, et al.. (2005). Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene. 24(54). 8025–8037. 73 indexed citations

15.

Lau, Loretta M. S., et al.. (2004). Factors Influencing Survival in Children With Recurrent Neuroblastoma. Journal of Pediatric Hematology/Oncology. 26(4). 227–232. 46 indexed citations

16.

Das, Bikul, et al.. (2003). In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. European Journal of Cancer. 39(17). 2556–2565. 58 indexed citations

17.

Dallas, Shannon, Xiaoping Zhu, Sylvain Baruchel, Lyanne C. Schlichter, & Reina Bendayan. (2003). Functional Expression of the Multidrug Resistance Protein 1 in Microglia. Journal of Pharmacology and Experimental Therapeutics. 307(1). 282–290. 72 indexed citations

18.

Hargrave, Darren, Éric Bouffet, Janet Gammon, et al.. (2003). Response to low dose temozolomide in radiation induced gliomatosis cerebri. Medical and Pediatric Oncology. 41(6). 562–564. 7 indexed citations

19.

Baruchel, Sylvain, et al.. (1992). Pseudomembranous colitis in sickle cell disease responding to exchange transfusion. The Journal of Pediatrics. 121(6). 915–917. 12 indexed citations

20.

Witkowska, H. Ewa, Bertram H. Lubin, Yves Beuzard, et al.. (1991). Sickle Cell Disease in a Patient with Sickle Cell Trait and Compound Heterozygosity for Hemoglobin S and Hemoglobin Quebec–Chori. New England Journal of Medicine. 325(16). 1150–1154. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact